HIV Drugs Market Share, Size, Key Players, Industry Overview, Analysis and Forecast to 2027

Comments · 94 Views

The HIV drugs market is expected to reach US$ 38.9 Billion by 2027, exhibiting a CAGR of 3.7% during 2022-2027.

According to IMARC Group’s latest report, titled “HIV Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027”, offers a comprehensive analysis of the industry, which comprises insights on the HIV drugs market share.

The global HIV drugs market size reached US$ 29.2 Billion in 2021. Looking forward, IMARC Group expects the market to reach US$ 38.9 Billion by 2027, exhibiting a CAGR of 3.7% during 2022-2027. Human immunodeficiency virus (HIV) refers to a retrovirus disease that can be transmitted from one individual to another through unprotected sexual intercourse or blood contact. It attacks the immune system by making the body vulnerable and damages the white blood cells (WBCs). If left untreated, then it might cause acquired immunodeficiency syndrome (AIDS). Currently, it can be treated with the support of antiretroviral therapies (ART) and medications. Amongst these drugs help in blocking the enzymes that HIV requires to spread in clusters of differentiation 4 (CD4) cells. Consequently, they are prescribed by healthcare practitioners to enhance the immune system, prevent its transmission and manage the symptoms.

Get a Free Sample Copy of this Report:

HIV Drugs Market Trends:

The growing prevalence of HIV due to blood contact or unprotected intercourse is primarily driving the market growth. Furthermore, the advent of antiretroviral therapy as a long-acting suppression (ATLAS) and increasing compliance rate of monthly dose treatment are fuelling the market growth. Moreover, significant investment in research and development (RD) initiatives by non-governmental organizations (NGOs) to innovate advanced treatment and government-run awareness programs are favoring the market growth. Such initiatives help educate the public regarding the causes, symptoms, and treatment of HIV. Additionally, several government activities to enhance HIV patients' access to diagnosis and treatment are contributing to market growth. Besides this, the emergence of low-cost generic medications that are chemically equivalent to branded drugs and the escalating use of HIV medications to treat the COVID-19 virus is propelling the market growth.

Competitive Landscape With Key Players:

The competitive landscape of the HIV drugs market has been studied in the report with the detailed profiles of the key players operating in the market.

Some of these key players include:     

  • Boehringer Ingelheim International GmbH,
  • Merck Co., Inc.,
  • ViiV Healthcare,
  • AbbVie, F. Hoffmann-La Roche Ltd.,
  • Teva Pharmaceutical Industries Ltd.,
  • Bristol-Myers Squibb Gilead Sciences, Inc.,
  • Johnson Johnson,
  • Cipla Limited,
  • Daiichi Sankyo,
  • Emcure,
  • Hetero Drugs,
  • Mylan.

Key Market Segmentation:

The report has segmented the global HIV drugs market on the basis of breakup by drug class, distribution channel and region.

Breakup by Drug Class:

  • Nucleoside Reverse Transcriptase Inhibitors
  • Multi-Class Combination Products
  • Protease Inhibitors
  • HIV Integrase Strand Transfer Inhibitors
  • Non-Nucleoside Reverse Transcriptase Inhibitors
  • Entry Inhibitors — CCR5 Co-Receptor Antagonist
  • Fusion Inhibitors and Others

Breakup by Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Others

Breakup by Region:

  • North America (United States, Canada)
  • Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
  • Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
  • Latin America (Brazil, Mexico, Others)
  • Middle East and Africa (United Arab Emirates, Saudi Arabia, Turkey, South Africa, Others)

Ask Analyst for Customization and Explore Full Report With TOC List of Figures:

Key Highlights of the Report:

  • Market Performance (2016-2021)
  • Market Outlook (2022-2027)
  • Market Trends
  • Market Drivers and Success Factors
  • Impact of COVID-19
  • Value Chain Analysis
  • Comprehensive mapping of the competitive landscape

If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.

About Us

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Our offerings include comprehensive market intelligence in the form of research reports, production cost reports, feasibility studies, and consulting services. Our team, which includes experienced researchers and analysts from various industries, is dedicated to providing high-quality data and insights to our clientele, ranging from small and medium businesses to Fortune 1000 corporations.

Contact US:

30 N Gould St, Ste R
Sheridan, WY 82801, USA
Email: [email protected]
Americas: +1-631-791-1145 | Europe Africa: +44-753-713-2163 | Asia: +91-120-433-0800